Current evidence suggests that mutations in the NRF2/KEAP1 gene may lead to poor prognosis in patients with lung cancer, such as resistance to radiotherapy and chemotherapy, but more specific evidence is needed to validate this 25,26. This evidence concerns the gene KEAP1 and lung cancer.